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Purpose: The incidence of single positive core prostate cancer at the time of biopsy ap-
pears to be increasing in the prostate-specific antigen (PSA) era. To determine the clin-
ical implication of this disease, we analyzed surgical and pathological characteristics 
in comparison with multiple positive core disease. 
Materials and Methods: Among 108 consecutive patients who underwent robotic radi-
cal prostatectomy following a diagnosis of prostate cancer based on a 12-core transrectal 
biopsy performed by the same method in a single institute, outcomes from 26 patients 
(Group 1) diagnosed on the basis of a single positive biopsy core and from 82 patients 
(Group 2) with multiple positive biopsy cores were analyzed. 
Results: The preoperative PSA value, Gleason score, prostate volume, and D’Amico’s
risk classification of each group were similar. The proportion of intermediate＋high- 
risk patients was 69.2% in Group 1 and 77.9% in Group 2 (p=0.22). Total operative time 
and blood loss were similar. Based on prostatectomy specimens, only 3 patients (11.5%) 
in Group 1 met the criteria for an indolent tumor (7.31% in Group 2). Although sim-
ilarities were observed during preoperative clinical staging (p=0.13), the final patho-
logic stage was significantly higher in Group 2 (p=0.001). The positive-margin rate was 
also higher in Group 2 (11.5% vs. 31.7%, p=0.043). Despite similarity in upstaging after 
prostatectomy in each group (p=0.86), upgrading occurred more frequently in Group 
1 (p=0.014, 42.5% vs. 19.5%). No clinical parameters were valuable in predicting 
upgrading. 
Conclusions: Most single positive core prostate cancer diagnoses in 12-core biopsy were 
clinically significant with similar risk stratification to multiple positive core prostate 
cancers. Although the positive-margin rate was lower than in multiple positive core 
disease, an increase in Gleason score after radical prostatectomy occurred more frequently.
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INTRODUCTION
The widespread use of serum prostate-specific antigen (PSA) 
screening associated with transrectal ultrasonography 
(TRUS) prostate biopsy has led to an increase in the pro-
portion of patients with low-stage, low-volume disease [1]. 
As with stage migration, the prevalence of single positive 
core disease appears to have shown a recent increase. 
Because tumor volume in single positive core disease may 
be relatively small, these tumors are expected to be clin-
ically insignificant, indolent tumors with a lower positive 
surgical margin. However, the clinical implication of such 
disease compared with that of multiple positive core dis-
ease has not yet been established. In an earlier study, a le-Korean J Urol 2010;51:671-676
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sion with a single positive biopsy containing a focus of 3 mm 
or less of moderately differentiated adenocarcinoma was 
suggested as indolent cancer [2]. In contrast, additional 
studies on a single microscopic focus of low-grade prostate 
cancer in preoperative biopsy have warned that not all of 
these patients have clinically insignificant disease in the 
final prostatectomy specimen [3,4]. However, most of the 
studies were based on a heterogeneous biopsy scheme, pre-
dominantly with sextant biopsy, or were especially focused 
on low-volume disease with low to intermediate Gleason 
grades as an attempt at preoperative identification of insig-
nificant disease. 
　Studies have shown that the use of more biopsy cores may 
minimize discrepancy with prostatectomy specimens ow-
ing to the sampling effect [5]. Currently, a 12-core scheme 
is recommended as a reasonable biopsy approach, provid-
ing an acceptable sampling of the prostate gland [6,7] with-
out increasing the complication rate [8]. Here then, to de-
termine the clinical implications of a single positive core 
in a 12-core scheme, we analyzed characteristics of single 
positive core prostate adenocarcinoma compared with 
multiple positive core disease in patients undergoing radi-
cal prostatectomy. 
MATERIALS AND METHODS
1. Patient population 
We performed robotic assisted radical prostatectomy 
(RARP) for a total of 144 patients from November 2008 
through December 2009. Because of possible effects on fi-
nal pathologic outcomes, patients who underwent prior 
hormone treatment, radiotherapy, or any ablative techni-
que were excluded in this series. Patients who underwent 
transrectal biopsy conducted by other institutions were al-
so excluded in this series. A total of 108 consecutive pa-
tients who underwent systemic 12-core biopsy at the De-
partment of Urology of our hospital and subsequent RARP 
for clinically localized or locally advanced prostate cancer 
(clinical stage T1c to T3b) from November 2008 through 
December 2009 were enrolled in this study. Clinical stage 
was assigned according to the 1992 TNM staging system 
on the basis of digital rectal examination or transrectal ul-
trasound findings. All RARP procedures were performed 
by a single full-faculty surgeon with robotic experience. 
RARP was performed by the standard transperitoneal ap-
proach with an interfacial technique by use of the da 
Vinci-S robot (Intuitive Surgical, Inc., Sunnyvale, CA, 
USA), as reported by Patel et al [9].
2. Prostate biopsy technique and histologic evaluation 
The 12-core biopsy scheme used in our institution includes 
a standard sextant, which was originally described by 
Hodge et al [10], as well as a lateral sextant scheme (lateral 
apex, lateral mid-gland, lateral base) [11]. The biopsy poli-
cy of our institution consists of an additional two more core 
biopsies in cases of palpable nodule or suspicious lesions 
in TRUS, and two more transitional zone biopsies in cases 
of repeat biopsy [6]. In this series, for standardization of the 
number of biopsy cores, patients with hypoechoic lesions 
on transitional zones, patients with finger-directed nod-
ules, or patients diagnosed by repeat biopsy were excluded. 
Patients received appropriate antibiotic coverage, and se-
lected patients underwent bowel preparation. All proce-
dures were performed by three dedicated urologists, each 
of whom has experience with over 300 cases of transrectal 
prostate biopsy by use of the 12-core scheme. Biopsies were 
performed under ultrasound guidance by 18-gauge, 2 cm 
long, Trucut core needle biopsy. Each biopsy core was sepa-
rately labeled to identify the location. TRUS-measured to-
tal prostate gland and transitional zone volumes were de-
termined by using the prostate ellipsoid formula. Cores 
from needle biopsy were interpreted by a single experi-
enced full-faculty uropathologist before radical prostatec-
tomy, without consensus interpretations. Prostate speci-
mens from RARP were also interpreted by the same full- 
faculty uropathologist. All radical prostatectomy speci-
mens, including the seminal vesicles and distal vas defer-
ens, were weighed, and the external surfaces were inked 
and submitted for pathological evaluation according to a 
modified Stanford protocol [12]. They were then fixed over-
night in 10% formalin. Following fixation, the apex and 
base were amputated and serially sectioned at 3 mm inter-
vals in the vertical, parasagittal plane. The seminal vesi-
cles were sectioned parallel to their junction with the pros-
tate and were entirely submitted for examination. The re-
maining prostate was sectioned serially, perpendicular to 
the long axis from the apex of the prostate to the base, and 
whole-mount sections were prepared. The greatest diame-
ter of the largest single focus of tumor was obtained by 
marking both ends of the tumor on the glass slide and meas-
uring this distance with a ruler marked in millimeters. The 
volume of carcinoma in the entire prostate was determined 
by using the grid method [13]. In this method, the sum of 
each area was multiplied by the thickness of the average 
slice. The level of capsular invasion, presence of seminal 
vesicle invasion, surgical margin status, and Gleason 
grade of the cancer were inspected. 
3. Data collection and analysis 
For enrolled patients, preoperative data, including biopsy 
results, clinical stage, initial serum PSA, operative out-
comes, and final pathological results, including margin 
positivity and pathologic stage, were collected prospectively. 
Results from patients diagnosed by a single positive biopsy 
core (Group 1) were compared with those of patients diag-
nosed by multiple positive cores (Group 2). On the basis of 
preoperative Gleason score, serum PSA, and clinical stage, 
patients were classified according to D’Amico’s risk strat-
ification scheme. Age, body mass index, PSA level, oper-
ation time, Gleason score, and estimated blood loss (EBL) 
were analyzed by independent t-test, and D’Amico’s risk 
classification was analyzed by Pearson’s chi-square test. 
The relation of pathologic stage and positive margin were 
calculated by chi-square test (linear by linear association). Korean J Urol 2010;51:671-676
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TABLE 1. Preoperative clinicopathologic characteristics and surgical results of each group
Group 1 (n=26) Group 2 (n=82) p-value
Age (yr)  63±5.8 62.8±6.5 0.898
a
Body mass index (kg/m
2) 24.7±2.3 23.8±2.4 0.101
a
ASA status 1.80±0.4 1.84±0.4 0.691
a
Prostate volume 29.9±9.9   29.2±10.0 0.818
a
Preoperative PSA (ng/ml) 7.7±3.9   8.7±5.6 0.418
a
Preoperative Gleason score 6.3±0.7   6.8±0.8 0.607
a
Total operative time (minutes) 205.3±101.1 211.9±71.6 0.232
a
Estimated blood loss (ml) 372.3±127.7 344.6±73.7 0.348
a
Duration of admission (d) 8.0±0.7   7.9±0.6 0.235
a
D’Amico’s risk stratification (%) Low: 30.8
Intermediate: 50.0
High: 19.2
Low: 22.1
Intermediate: 42.7
High: 35.2
0.17
b
Intermediate＋high: 69.2 Intermediate＋high: 77.9 0.22
b
Positive-margin rate (%) 11.5 31.7 0.043
b
ASA: The American Society of Anesthesiologists Physical Status Classification System, PSA: prostate-specific antigen, Group 1: single
positive core, Group 2: multiple positive cores, 
a: Student’s t-test, 
b: Pearson’s chi-square test
TABLE 2. Preoperative clinical stage and postoperative pathologic stage in each group
Stage
Group 1 (n=26) Group 2 (n=82)
Preoperative 
clinical stage  (%)
Preoperative pathologic 
stage  (PSM)
Postoperative 
clinical stage  (%)
a
Postoperative pathologic 
stage  (PSM)
b
T1c 11 (43.4) 22 (23.4)
T2a 4 (13.1) 11 (0) 6 (6.5) 8 (0)
T2b 2 (4.3) 5 (0) 12 (12.9) 9 (2)
T2c 6 (26.1) 8 (1) 31 (33.8) 29 (5)
T3a 2 (8.7) 1 (1) 10 (11.7) 26 (12)
T3b 1 (4.3) 1 (1) 1 (1.3) 5 (3)
T3c 0 0 (0) 0 4 (3)
T4 0 0 (0) 0 1 (1)
Total 26 26 (3) 82 82 (26)
PSM : positive surgical margin, 
a: comparison of preoperative clinical stage in each group. p=0.126, 
b: comparison of postoperative patho-
logic stage in each group. p=0.001
Correlation analysis was used to predict the relationship 
of the number of positive cores and the positive-margin 
rate. Statistical significance in this study was set at p＜ 
0.05. All reported p-values are 2-sided. All analyses were 
performed with SPSS, ver. 12.0 (SPSS Inc., Chicago, IL, 
USA). 
RESULTS
Among the patients enrolled, 26 patients had a single pos-
itive core in the 12-core biopsy (Group 1), and 82 patients 
had multiple positive cores (Group 2). The perioperative 
characteristics of each group are summarized in Table 1. 
Serum PSA (7.7±3.9 vs. 8.7±5.6 ng/ml), Gleason score (6.3± 
0.7 vs. 6.8±0.8), and prostate volume (29.9±9.9 vs. 29.2± 
10.0) were similar in each group. A total of 94 patients had 
clinically localized disease, and 14 had locally advanced 
disease. Classification of patients by D’Amico’s classi-
fication showed that the proportion of patients in each risk 
group was similar (Pearson’s chi-square test, p=0.17). In 
Group 1, only 30.8% of patients were stratified as low risk. 
The proportion of intermediate＋high risk patients was 
69.2% in Group 1 and 77.9% in Group 2 (p=0.22) (Table 1). 
　Surgical results showed no significant difference be-
tween the two groups in total operative time (205.3±101 vs. 
211.9±71.6 minutes), estimated blood loss (372.3±127.7 vs. 
344.6±73.7 ml), or hospitalization duration (8.0±0.7 vs. 
7.9±0.6 days).
　On the basis of prostatectomy specimens, only 3 patients 
(11.5%) in Group 1 met the criteria for an indolent tumor 
(7.31% in Group 2), which was defined by a tumor volume 
below 0.5 cc and Gleason score below 7 [14]. Although sim-
ilarity in preoperative clinical stage was observed (p=0.13), 
pathologic stage based on prostatectomy specimens was 
significantly higher in Group 2 (p=0.001) (Table 2). Changes 
in stage after prostatectomy were similar in each group Korean J Urol 2010;51:671-676
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FIG. 1. (A) Change in stage after prostatectomy. Changes in stage
after prostatectomy were similar in each group (p=0.86); 61.5% 
of Group 1 and 57.3% of Group 2 experienced upstaging after 
prostatectomy. Change in Gleason score after prostatectomy 
showed a significant difference between each group (p=0.014). (B)
Changes in Gleason grade after prostatectomy. Upgrading after
prostatectomy occurred more frequently in Group 1 (42.5%), than
in Group 2 (19.5%).
FIG. 2. Relationship of margin positivity with number of positive
cores in a 12-core systematic transrectal biopsy scheme. A signi-
ficant positive correlation between the number of positive cores 
and the positive-margin rate was found in Group 2 (correlation
analysis, Spearman’s correlation coefficient=0.918, p=0.001).
(p=0.86); 61.5% in Group 1 and 57.3% in Group 2 experi-
enced upstaging (Fig. 1A). However, change in Gleason 
score showed a significant difference (p=0.014). Upgrading 
was higher in Group 1 (42.5%) than in Group 2 (19.5%) (Fig. 
1B). According to both the univariate and the multivariate 
analysis, this change had no correlation with preoperative 
clinical parameters, including serum PSA, prostate vol-
ume, clinical stage, biopsy Gleason score, and tumor vol-
ume in biopsy specimens. 
　The positive-margin rate was significantly higher in 
Group 2 (11.5% vs. 31.7%, p=0.043). In Group 1, whereas 
only one patient (4.2%) among 24 with pathologically lo-
calized disease had positive margins, there were 7 patients 
(15.2%) among 46 with localized disease in Group 2. There 
was a significant positive correlation between the number 
of positive cores and the positive-margin rate in Group 2 
(correlation analysis, Spearman’s correlation coefficient= 
0.918, p=0.001) (Fig. 2).
DISCUSSION
Although the clinical implication has not been clearly de-
termined, the incidence of single positive core prostate can-
cer appears to be increasing in the PSA screening era. In 
a population-based screening study conducted by the 
Rotterdam section of the European randomized study on 
screening of prostate cancer, the proportion of focal can-
cers, defined as those involving less than 3 mm in a single 
core without Gleason grade 4 or 5 during the second screen-
ing after 4 years, increased from 16% to 29% of all detected 
cancer [14].
　If physicians are to recommend a specific management 
to patients with prostate cancer, an accurate estimation of 
risk is essential. Because tumor volume in single positive 
core prostate cancer may be relatively small, the disease 
is expected to be curable, toward low-risk patient groups 
in risk stratification, as shown in a 6-core scheme. Active 
surveillance with delayed intervention appears to be a via-
ble option for carefully selected men with low-risk prostate 
cancer. Good-risk prostate cancer, defined as a Gleason 
score of 6 or less, PSA of 10, and T1c to T2a, now constitutes 
50% of newly diagnosed prostate cancer [15]. In most of 
these patients, the disease is indolent and slow growing. 
The challenge is to identify those patients who are unlikely 
to experience significant progression while offering radical 
therapy to those who are at risk. Currently, the best means 
of selecting such patients for definitive therapy is an ap-
proach based on the interpretation of PSA kinetics and re-
peat biopsy during a period of surveillance [16]. The ap-
proach of active surveillance with selective delayed inter-
vention based on PSA doubling time represents a practical 
compromise between radical therapy for all (which results 
in overtreatment of patients with indolent disease) and 
watchful waiting with palliative therapy only (which re-
sults in undertreatment of those with aggressive disease). 
Clinical judgement incorporating patient comorbidity, life 
expectancy, and attitude towards quality versus quantity 
of life is required in making this recommendation. Howev-
er, our study and many other published studies have re-
ported that upstaging in pathology and Gleason score up-
grading occurs after radical prostectomy [17]. D'Amico et 
al mentioned that it is not appropriate to do active surveil-
lance for prostate cancer over a Gleason score of 7, because 
of the high biochemical and pathological progression  rate 
[18]. Thus, it is hard to define the group of active survei-
llance.
　However, several series that focused on a single focus as 
a potential variable in the prediction of insignificant pros-
tate cancer reported outcomes in contrast with these Korean J Urol 2010;51:671-676
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assumptions. Analysis of the final pathologic outcome for 
27 patients who had only an identifiable Gleason grade or 
a tumor confined to only one core of the sextant biopsy speci-
men by Bruce et al found that 26% of patients had extra-
capsular disease [19]. Thong et al reported on a total of 192 
patients with Gleason score 6 prostate cancer involving 5% 
or less of one biopsy core: overall, 42 patients (22%) were 
upgraded or upstaged after surgery [20]. In a microfocus 
(5% or less of cancer in a single core) series, D’Amico et al 
and Boccon-Gibod et al failed to identify preoperative clin-
ical factors for prediction of unfavorable final pathological 
findings [3,21]. Recently, Pepe et al analyzed prostatec-
tomy specimens from 55 patients with a single neoplastic 
microfocus in saturation biopsies with a median of 30 cores 
[22]. Histological examination showed that 87.3% of pa-
tients had significant cancer, with the presence of extra-
capsular extension in 27.3% and positive surgical margins 
in 14.5%.
　As an explicit extension of these findings, our series pro-
vides additional evidence to support the clinical significance 
of single positive core disease in preoperative biopsy. Risk 
stratification for the single positive core group was com-
parable with that of the multiple positive core group; many 
of them were clinically moderate or high risk in this series. 
Among 26 patients in the single positive core group, only 
three patients had pathologically indolent tumors. There 
are several plausible explanations for our findings. The in-
herent sampling error in prostate needle biopsies contrib-
utes to this, due to the fact that prostate cancer is usually 
associated with multifocal lesions [23]. Additionally, when 
the cancer is misinterpreted as being single positive core 
disease on the basis of a biopsy specimen, this would be sec-
ondary to a small volume of cancer that was not adequately 
sampled and missed by the needle. In a study of whole 
mount, serial sectioned radical prostatectomy specimens, 
Cupp et al found significant variability in actual prostate 
cancer volume for a given percent of biopsy core involve-
ment [24]. Moreover, there is evidence to show that com-
pared with multifocal disease, single-focus prostate cancer 
differs in its clinicopathological behavior. In a comparison 
of 1,056 radical prostatectomy specimens with multifocal 
disease and 103 specimens with single focus disease.
　One of the advantages of the present series is the use of 
an identical process in the conduct of the prostate biopsy. 
All biopsies were taken from the same 12-core scheme by 
experienced urologists in a single institution. As expected, 
when a smaller volume of prostate tissue is sampled, the 
correlation between biopsy findings and prostatectomy 
pathology shows more variability, depending on the num-
ber of biopsy cores [3]. Thus, studies based on a heteroge-
neous biopsy scheme may have potential inherited bias. 
Since the introduction of a systematic sextant biopsy 
scheme, with the aim of increasing cancer detection, sev-
eral modifications in biopsy techniques and number and lo-
calization of biopsy cores have been described. However, al-
though more biopsy cores ensure higher sensitivity, higher 
complication rates and poorer patient comfort are major 
well-known drawbacks. Twelve-core biopsy is a commonly 
used scheme and is recommend by currently established 
guidelines [6,7]. This scheme has been validated in a large 
study of 2,299 patients involving 167 community-based ur-
ologists; results from a randomized trial found that in-
creasing the number of cores taken from 6 to 12 did not sub-
stantially increase complications or delay return to normal 
activities [8]. Moreover, to avoid the overall risk of under-
staging or undergrading, at least a 12-core scheme should 
be performed [25].
　Considering that the Gleason scoring system is one of the 
most important prognostic factors in prostate cancer, the 
increase in the rate of upgrading in the single positive core 
group is noteworthy. Studies have shown that biopsy grad-
ing, when compared with matched surgical grades, suffers 
from a significant rate of upgrading, ranging from 27% to 
57% [26]. However, according to our analysis, there was no 
preoperative parameter for prediction of upgrading of 
Gleason score. 
　Taken together, our findings suggest that it might be clin-
ically beneficial to treat single positive core disease at the 
time of biopsy in the same manner as multiple core disease. 
Single positive core disease tends to be clinically significant 
cancer with a similar risk stratification, with a high poten-
tial for upgrading after prostatectomy, without clinical fac-
tors for prediction of upgrading. Because treatment deci-
sions for prostate cancer are based on our ability to evaluate 
the prognosis of individual patients, gaining a better un-
derstanding of the basis of pretreatment biopsy is of the ut-
most importance. Considering the significantly lower mar-
gin positivity, our data imply the potential benefits of radi-
cal resection in patients diagnosed by a single positive core, 
because these patients may have a higher possibility of cu-
rative resection than their multiple positive core counter-
parts. However, these data were obtained from a single cen-
ter by a single surgeon. Further large-scale, prospective, 
multi-institutional trials are necessary for verification of 
the clinical and pathological characteristics of patients di-
agnosed with single positive core prostate cancer. 
CONCLUSIONS
In summary, most single positive core prostate cancers 
that were diagnosed by using 12-core transrectal biopsy 
were shown to be clinically significant cancers in the radi-
cal prostatectomy specimens with similar preoperative 
risk stratification compared to multiple positive core 
disease. At the time of the prostatectomy, the positive-mar-
gin rate was lower; however, an increase in Gleason score 
occurred more frequently. These characteristics imply that 
it might be clinically beneficial to treat this disease in the 
same manner as multiple positive core disease, including 
radical resection, rather than watchful waiting. 
Conflicts of Interest
The authors have nothing to disclose.Korean J Urol 2010;51:671-676
676 Ahn et al
REFERENCES
1. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, 
Henning JM, et al. The contemporary management of prostate 
cancer in the United States: lessons from the cancer of the pros-
tate strategic urologic research endeavor (CapSURE), a national 
disease registry. J Urol 2004;171:1393-401.
2. Terris MK, McNeal JE, Stamey TA. Detection of clinically sig-
nificant prostate cancer by transrectal ultrasound-guided sys-
tematic biopsies. J Urol 1992;148:829-32.
3. D’Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. 
Pathologic findings and prostate specific antigen outcome after 
radical prostatectomy for patients diagnosed on the basis of a sin-
gle microscopic focus of prostate carcinoma with a Gleason score 
≤7. Cancer 2000;89:1810-7.
4. Lee AK, Doytchinova T, Chen MH, Renshaw AA, Weinstein M, 
Richie JP, et al. Can the core length involved with prostate cancer 
identify clinically insignificant disease in low risk patients diag-
nosed on the basis of a single positive core? Urol Oncol 2003;21: 
123-7.
5. Bulbul MA, El-Hout Y, Haddad M, Tawil A, Houjaij A, Bou Diab 
N, et al. Pathological correlation between needle biopsy and radi-
cal prostatectomy specimen in patients with localized prostate 
cancer. Can Urol Assoc J 2007;1:264-6.
6. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham 
JA, et al. NCCN clinical practice guidelines in oncology: prostate 
cancer. J Natl Compr Canc Netw 2010;8:162-200.
7. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid 
HP, et al. EAU guidelines on prostate cancer. Actas Urol Esp 
2009;33:113-26.
8. O’Connell MJ, Smith CS, Fitzpatrick PE, Keane CO, Fitzpatrick 
JM, Behan M, et al. Transrectal ultrasound-guided biopsy of the 
prostate gland: value of 12 versus 6 cores. Abdom Imaging 2004; 
29:132-6.
9. Patel VR, Thaly R, Shah K. Robotic radical prostatectomy: out-
comes of 500 cases. BJU Int 2007;99:1109-12.
10. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random system-
atic versus directed ultrasound guided transrectal core biopsies 
of the prostate. J Urol 1989;142:71-4.
11. Presti JC Jr, O’Dowd GJ, Miller MC, Mattu R, Veltri RW. 
Extended peripheral zone biopsy schemes increase cancer de-
tection rates and minimize variance in prostate specific antigen 
and age related cancer rates: results of a community multi-prac-
tice study. J Urol 2003;169:125-9.
12. Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Ayala 
AG. Recommendations for the reporting of resected prostate 
carcinomas. Association of Directors of Anatomic and Surgical 
Pathology. Am J Clin Pathol 1996;105:667-70.
13. Humphrey PA, Vollmer RT. lntraglandular tumor extent and 
prognosis in prostatic carcinoma: application of a grid method to 
prostatectomy specimens. Hum Pathol 1990;21:799-804.
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathological 
and clinical findings to predict tumor extent of nonpalpable (stage 
T1c) prostate cancer. JAMA 1994;271:368-74.
15. Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, 
Schröder FH, et al. Effect of the correction for non-compliance and 
contamination on the estimated reduction of metastatic prostate 
cancer within a randomized screening trial (ERSPC section rot-
terdam). Int J Cancer 2010;127:2639-44.
16. Klotz LH, Nam RK. Active surveillance with selective delayed in-
tervention for favorable risk prostate cancer: clinical experience 
and a ‘number needed to treat’ analysis. Can J Urol 2006;13(Suppl 
1):48-55.
17. Kim SC, Hong JH, Song K, Jeong IG, Song C, Kim CS, et al. 
Predictive factors for upgrading or upstaging in biopsy Gleason 
score 6 prostate cancer. Korean J Urol 2009;50:836-42.
18. Hong SK, Han BK, Lee ST, Kim SS, Min KE, Jeong SJ, et al. 
Prediction of Gleason score upgrading in low-risk prostate can-
cers diagnosed via multi (＞  or =12)-core prostate biopsy. World 
J Urol 2009;27:271-6.
19. Bruce RG, Rankin WR, Cibull ML, Rayens MK, Banks ER, Wood 
DP Jr. Single focus of adenocarcinoma in the prostate biopsy 
specimen is not predictive of the pathologic stage of disease. 
Urology 1996;48:75-9.
20. Thong AE, Shikanov S, Katz MH, Gofrit ON, Eggener S, Zagaja 
GP, et al. A single microfocus (5% or less) of Gleason 6 prostate 
cancer at biopsy--can we predict adverse pathological outcomes? 
J Urol 2008;180:2436-40. 
21. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, 
Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of bi-
opsy and radical prostatectomy specimen features. Eur Urol 
2005;48:895-9.
22. Pepe P, Fraggetta F, Galia A, Candiano G, Grasso G, Aragona F. 
Is a single focus of low-grade prostate cancer diagnosed on satu-
ration biopsy predictive of clinically insignificant cancer? Urol Int 
2010;84:440-4.
23. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. 
Ability of sextant biopsies to predict radical prostatectomy stage. 
Urology 1998;51:759-64.
24. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume 
of prostate cancer in the biopsy specimen cannot reliably predict 
the quantity of cancer in the radical prostatectomy specimen on 
an individual basis. J Urol 1995;153:1543-8.
25. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal 
systematic prostate biopsy scheme should include 8 rather than 
6 biopsies: results of a prospective clinical trial. J Urol 2000;163: 
163-6.
26. Gleason DF. Undergrading of prostate cancer biopsies: a paradox 
inherent in all biologic bivariate distributions. Urology 1996;47: 
289-91.